BRIEF published on 05/13/2025 at 07:05, 10 months 14 days ago Innate Pharma Reports First Quarter 2025 Results Financial Results Clinical Trials Innate Pharma Sanofi Investment Lacutamab FDA
BRIEF published on 05/13/2025 at 07:05, 10 months 14 days ago Innate Pharma publie ses résultats du premier trimestre 2025 Résultats Financiers Essais Cliniques Innate Pharma Investissement Sanofi Lacutamab FDA
PRESS RELEASE published on 05/13/2025 at 07:00, 10 months 14 days ago Informations privilégiées / Communiqué sur comptes, résultats Innate Pharma annonce ses résultats financiers du premier trimestre 2025 et les avancées de son portefeuille, incluant des investissements et des études cliniques. Une conférence téléphonique est prévue à 14h00 CEST Résultats Financiers Conférence Téléphonique Portefeuille Études Cliniques Innate Pharma
PRESS RELEASE published on 05/13/2025 at 07:00, 10 months 14 days ago Inside Information / News release on accounts, results Innate Pharma reports Q1 2025 business update with €15 million investment by Sanofi, FDA Breakthrough Therapy Designation for lacutamab, and cash position of €72.5 million FDA Financial Results Sanofi Innate Pharma Q1 2025
BRIEF published on 05/02/2025 at 15:27, 10 months 24 days ago Sanofi augmente sa participation dans Innate Pharma Capital Actions Franchissement De Seuils Sanofi Innate Pharma
BRIEF published on 05/02/2025 at 15:27, 10 months 24 days ago Sanofi increases its stake in Innate Pharma Capital Actions Crossing Thresholds Sanofi Innate Pharma
PRESS RELEASE published on 05/02/2025 at 15:22, 10 months 24 days ago Franchissement de seuils Déclaration de franchissement de seuils par Sanofi pour Innate Pharma via augmentation de capital Augmentation De Capital Franchissement De Seuils Sanofi Innate Pharma
BRIEF published on 04/29/2025 at 21:05, 10 months 27 days ago Innate Pharma Presents Promising Preclinical Data for IPH4502 at AACR 2025 Preclinical Data Innate Pharma IPH4502 Nectin-4 Antibody Drug Conjugate
BRIEF published on 04/29/2025 at 21:05, 10 months 27 days ago Innate Pharma présente des données précliniques prometteuses pour IPH4502 à l'AACR 2025 Innate Pharma Données Précliniques Conjugué Anticorps-médicament IPH4502 Nectine-4
PRESS RELEASE published on 04/29/2025 at 21:00, 10 months 27 days ago Inside Information / Other news releases Innate Pharma presents preclinical data for IPH4502, a Nectin-4 targeting ADC, showing superior anti-tumor efficacy in multiple cancer models at AACR 2025 Annual Meeting Preclinical Data Innate Pharma IPH4502 AACR 2025 Nectin-4 ADC
Published on 03/27/2026 at 12:00, 15 minutes ago Temas Appoints Scientific Advisory Board to Accelerate RCL Commercialisation and Global Development
Published on 03/27/2026 at 11:00, 1 hour 15 minutes ago RE Royalties Announces Strategic Review to Evaluate Path for Long-Term Value Creation
Published on 03/27/2026 at 09:30, 2 hours 45 minutes ago Amap Street Stars Launches Macao Authentic Delicacies Ranking to Drive Cultural-Tourism Innovation in the Greater Bay Area
Published on 03/27/2026 at 08:05, 4 hours 10 minutes ago Battery X Metals Announces Corporate Awareness Engagements
Published on 03/27/2026 at 11:45, 29 minutes ago Second National Showcase of Outstanding Works from China’s Rare Operatic Genres Held
Published on 03/27/2026 at 11:45, 29 minutes ago Deuxième édition du Festival des chefs-d’œuvre des genres rares de l’opéra chinois Un événement dédié aux opéras traditionnels en voie de disparition
Published on 03/27/2026 at 11:40, 34 minutes ago Disposal of shares in Pension Insurance Corporation Group Limited
Published on 03/27/2026 at 11:19, 55 minutes ago The Payments Group Holding advances strategic initiatives successfully
Published on 03/27/2026 at 10:45, 1 hour 29 minutes ago Athora Group completes acquisition of Pension Insurance Corporation Group and announces plans to relocate headquarters to the UK
Published on 03/27/2026 at 07:00, 5 hours 15 minutes ago WEB SA - CONVOCATION ASSEMBLEE GENERALE ORDINAIRE EXERCICE 2025 - 28/04/2026
Published on 03/26/2026 at 18:17, 17 hours 58 minutes ago Eiffage se renforce au capital de Getlink et porte sa participation à 29,40 % du capital
Published on 03/26/2026 at 18:17, 17 hours 58 minutes ago Eiffage strengthens its position in Getlink capital
Published on 03/26/2026 at 18:00, 18 hours 15 minutes ago Arrêté des comptes au 31 décembre 2025 et perspectives 2026
